Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025

The findings of a prospective study on 93 patients (66% women, 75% PAH, 25% CTEPH, 57±17 years), all on pulmonary hypertension-targeted oral medication, between 2013 and 2023, were recently published in the British Medical Journal Open Respiratory Research. These reveal that mean MPR (Medication Possession Ratio) and self-reported adherence were overall high, with 78% of patients […]

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025 Read Post »

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox, International Journal of Cardiology Congenital Heart Disease, March 2025

Pulmonary arterial hypertension (PAH), once seen mostly in young, healthy women, is now common among older adults with comorbidities in North America and Europe. In contrast, Latin American patients remain younger and healthier, with fewer related conditions. Possible Reasons Current Situation Latin American pulmonary arterial hypertension patients have: Future Concerns Rising obesity and aging populations

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025

An article published in the New England Journal of Medicine on March 31 titled “Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death” reports on the findings of ZENITH, a phase 3 trial which evaluated sotatercept as an add-on therapy for high-risk pulmonary arterial hypertension patients (functional class II-IV) already on maximum

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025 Read Post »

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025

A very important update on the phase 3 ZENITH trial for Winrevair (sotatercept) in pulmonary arterial hypertension was presented today at the American College of Cardiologists Annual Scientific Session in Boston, USA. The ZENITH trial evaluated Winrevair compared to placebo in adults with PAH, WHO Group 1, functional class III or IV, at high risk

Breaking news! Important update on the ZENITH trial on Winrevair (sotatercept) in pulmonary arterial hypertension from the American College of Cardiologists Scientific Annual Scientific Session, March 31, 2025 Read Post »

Latest edition on “Mariposa” the quarterly magazine of the European PH organisation PHA Europe, is now out covering the annual conference, World PH Day and much more

In the Editor’s Note to “Mariposa” Hall Skaara, project manager at PHA Europe, highlights the organisation’s key 2024 achievements: Download the full issue of the magazine at this link on the PHA Europe website

Latest edition on “Mariposa” the quarterly magazine of the European PH organisation PHA Europe, is now out covering the annual conference, World PH Day and much more Read Post »

How tech improvements can benefit the chronic illness community, a testimony from Anna Jeter for Pulmonary Hypertension News, March 17, 2025

Anna Jeter, author of a recent article for Pulmonary Hypertension News, underwent a heart and lung transplant in 2018, and has since embraced smartwatch technology, and discovered valuable health management applications: Her smartwatch and phone helps track: Additional technology benefits include: Anna says she is thankful to live in a time of technological advancement that

How tech improvements can benefit the chronic illness community, a testimony from Anna Jeter for Pulmonary Hypertension News, March 17, 2025 Read Post »

The Association of Organ Procurement Organizations (AOPO) stresses how important language is organ donation and how it can save lives, March 27, 2025

Communication plays a crucial role in organ donation processes. According to the Association of Organ Procurement Organizations (AOPO), terminology choices can significantly impact public perception, potentially creating unnecessary fear that reduces donation rates. AOPO advocates for language that honors donors’ contributions and builds public confidence in the donation system. Recommended Terminology Shifts Surgical Procedure Terminology

The Association of Organ Procurement Organizations (AOPO) stresses how important language is organ donation and how it can save lives, March 27, 2025 Read Post »

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025

Imatinib for pulmonary arterial hypertension was the first antiproliferative approach in this condition’s treatment and may still be relevant today despite its complicated history. Originally developed as a cancer therapy (tyrosine kinase inhibitor), it showed very good results in pulmonary arterial hypertension, creating a lot of expectation when the IMPRES study was presented at the

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose Finding Phase 2 Study, American Journal for Respiratory Critical Care Medicine, March 2025 Read Post »

The US Food and Drug Administration (FDA) has accepted the new drug application resubmission for YUTREPIA™ (treprostinil) inhalation powder, March 28, 2025

Link: Liquidia Corporation announced on March 28, 2025, that the US Food and Drug Administration has accepted its resubmitted new drug application for YUTREPIA (treprostinil) inhalation powder. The treatment targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA had previously granted tentative approval for both indications (see our

The US Food and Drug Administration (FDA) has accepted the new drug application resubmission for YUTREPIA™ (treprostinil) inhalation powder, March 28, 2025 Read Post »

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025

The case study reported in a recent article for the American Journal of Case Reports, describes a 32-year-old male patient with idiopathic pulmonary arterial hypertension (IPAH) who presented with hoarseness. The hoarseness was attributed to Ortner syndrome, where an enlarged pulmonary artery compressed the left recurrent laryngeal nerve, causing left vocal fold paralysis. Diagnostic workup

Hoarseness as a rare symptom of idiopathic pulmonary arterial hypertension due to Ortner Syndrome, American Journal of Case Reports, March 28, 2025 Read Post »

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT) speaking at TEDX Sweden, March 29, 2025

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT), is schedule to give a TedX talk about ”The power of three: death, life and the gift in between”. He has written on his LinkedIn page that he will recount three stories “that capture

Gabi Oniscu, Professor of Transplantation Surgery at the Karolinska Institutet, Sweden, and President of the European Society for Organ Transplantation (ESOT) speaking at TEDX Sweden, March 29, 2025 Read Post »

The first edition of the year of the UK’s Pulmonary Hypertension’s EMPHASIS magazine is now out

EMPHASIS is the quarterly magazine of the UK Pulmonary Hypertension Association, PHA UK. You can read it at this link on the PHA UK website. This edition contains news of patient meetings, an update on sotatercept and an analysis of the future of research, a number of patient stories, an article on self identity and

The first edition of the year of the UK’s Pulmonary Hypertension’s EMPHASIS magazine is now out Read Post »

A large-scale randomised controlled trial in Taiwan reveals that the use of an artificial intelligence-enabled electrocardiogram alert system can significantly reduce mortality in hospitalized patients, Nature Medicine

This article on the use of an artificial intelligence alert system is not new but it was mentioned during the recent European Society of Cardiology CRT – Cardiovascular Round Table – on the them of AI in cardiovascular care, which took place on March 26-27, 2025 (link) The primary clinical hypothesis of this randomised controlled

A large-scale randomised controlled trial in Taiwan reveals that the use of an artificial intelligence-enabled electrocardiogram alert system can significantly reduce mortality in hospitalized patients, Nature Medicine Read Post »

Patient participation at the 2nd European Society of Cardiology CRT, Cardiovascular Round Table, on “How can cardiologists take the lead in moving AI forward”, Guermantes, France, March 26-27, 2025

The European Society of Cardiology‘s 2025 CRT – Cardiovascular Round Table – took place on 26-27 March in Guermantes, France. This gathering united approximately 80 participants representing the scientific community, pharma and tech industries, and patient advocates, to explore the transformative theme “Working together to move forward AI in cardiology.” The meeting carefully balanced informative

Patient participation at the 2nd European Society of Cardiology CRT, Cardiovascular Round Table, on “How can cardiologists take the lead in moving AI forward”, Guermantes, France, March 26-27, 2025 Read Post »

March is Nutrition Month in the US, here are some tips from the US Pulmonary Hypertension Association, PHA

March is National Nutrition Month in the US, and the Pulmonary Hypertension Association has shared a LinkedIn post highlighting nutrition awareness for pulmonary hypertension patients. The organization encourages patients to be especially mindful of their dietary choices, as certain foods and vitamins can adversely interact with pulmonary hypertension medications, worsen edema (fluid retention), or exacerbate

March is Nutrition Month in the US, here are some tips from the US Pulmonary Hypertension Association, PHA Read Post »

Pregnancy and pulmonary arterial hypertension: Management challenges, International Journal of Cardiology Congenital Heart Disease, March 2025

This article, published in the International Journal of Cardiology Congenital Heart Disease in March 2025, discusses pulmonary hypertension in pregnancy, historically associated with poor outcomes, and provides recent evidence suggesting that the prognosis varies based on underlying cause and severity. The authors emphasize the need for individualized care through a multidisciplinary team approach at tertiary

Pregnancy and pulmonary arterial hypertension: Management challenges, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

Latest edition of “Pathlight”, the US Pulmonary Hypertension Association’s quarterly magazine, now out!

The latest issue of the quarterly Pathlight magazine of the US Pulmonary Hypertension Association, the PHA, celebrates pulmonary hypertension heroes. As National Volunteer Month approaches, the association acknowledges the people who make this organization a success. This issue also includes articles about imaging innovations, managing medication side effects and swimming with subcutaneous therapy.  To receive

Latest edition of “Pathlight”, the US Pulmonary Hypertension Association’s quarterly magazine, now out! Read Post »

How family dynamics are affected in the case of a genetic pulmonary arterial hypertension diagnosis: interview and focus group highlights, European Respiratory Journal Open research, March 24, 2025

A study titled “Navigating family dynamics and ethical considerations in genetic diagnosis of pulmonary arterial hypertension: insights from in-depth semi-structured interviews”, published on the ERJ Open research on March 24, 2025, examines the impact of genetic diagnosis on families affected by pulmonary arterial hypertension (PAH). Researchers interviewed 63 stakeholders across 53 interviews and focus groups

How family dynamics are affected in the case of a genetic pulmonary arterial hypertension diagnosis: interview and focus group highlights, European Respiratory Journal Open research, March 24, 2025 Read Post »

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025

In a multicenter study from the FOCUS-PAH registry (2001-2022), researchers examined sex differences among 410 pulmonary arterial hypertension patients, and found that women represented 2 out of 3 patients (66.6 %) vs 33.4%). The findings, published in the International Journal of Cardiology on March 20, 2025 in an article titled “Sex differences in pulmonary arterial

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025 Read Post »

Advancing pulmonary hypertension care at the ERN-Lung Annual Board meeting, Paris, March 24-25, 2025

The annual Board meeting of the ERN-LUNG – European Reference Network for rare respiratory diseases, took place in Paris on March 24-25, 2025, with over 100 participants, not only from the EU but also UK, US and Canada. Two European patient representatives, Pisana Ferrari and Hall Skaara, (2nd and 3rd from left in the cover

Advancing pulmonary hypertension care at the ERN-Lung Annual Board meeting, Paris, March 24-25, 2025 Read Post »

TRANSLATE »
Scroll to Top